Andere Sprachen Connect Biopharma Holdings Limited

Aktien

A2QR0E

US2075231017

CNTB

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 03.05.2024			% 5 Tage	% 1. Jan.
1,59 ^USD	+2,58 %		+18,66 %	+34,75 %

17.04.	CONNECT BIOPHARMA HOLDINGS LIMITED : HC Wainwright bekräftigt seine Kaufempfehlung	ZM
16.04.	Connect Biopharma Holdings Limited berichtet über die Ergebnisse für das Geschäftsjahr zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management	02.05.
Sector Update: Health Care Stocks Retreating Late Afternoon	17.04.
Sector Update: Health Care	17.04.
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer	17.04.
Connect Biopharma Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	16.04.
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update	16.04.
ADRs Advance, Eco Wave Power Global AB Climbs 213.4%	08.04.
ADRs Advance; Connect Biopharma Climbs 19%	05.04.
ADRs Close Lower; Moatable Inc. Declines 33.3%	04.04.
ADRs End Higher; Connect Biopharma Climbs 26%	01.04.
ADRs End Higher; Connect Biopharma Holdings Climbs 21%	27.03.
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference	19.03.
ADRs End Flat; Tuniu Climbs 16%	23.02.
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors	12.02.
Connect Biopharma Holdings Limited Appoints James Huang to Board of Directors	12.02.
ADRs End With Gains; TC BioPharm Climbs 38%	09.02.
Connect Biopharma Holdings Limited Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-To-Severe Persistent Asthma	12.12.
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma	12.12.
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023	11.12.
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management	30.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Connect Biopharma Holdings Limited

Aktien

A2QR0E

US2075231017

CNTB

Andere Sprachen

Filter